• Cutting-edge platform technology leveraging advanced molecular dynamics to uncover protein metastates and reveal novel binding sites in difficult to target proteins.
• Combining RxPlorer™ with our in vitro capabilities, RxCelerate can deliver rapid hit identification and screening in 2 months.
Cambridge, UK and Cambridge, MA – 24/3/26 1pm GMT
RxCelerate, a leading international outsourced drug discovery and development provider, today announced the launch of RxPlorer™: a new technology for finding small molecule hits, particularly against challenging, previously undruggable targets.…
We are pleased to announce the winners of the One Nucleus Awards 2026! The awards took place on 29 March in London.The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders.
Many congratulations to the winners and finalists:
Best Therapeutic R&D Programme of the Year⭐Winner: Resolution Therapeutics⭐Finalists: Serenatis Bio, TRIMTECH Therapeutics
Best Use of Emerging Technology of the Year⭐Winner: Nuclera⭐Finalists: Ignota Labs, Constructive Bio
Best Industry and Not-for-Profit…
New parliamentary scrutiny of the UK’s innovation landscape has reinforced longstanding concerns about how investment in innovation is distributed across the country, with Pioneer Group, a specialist in technology infrastructure and venture building, urging swift action to address persistent barriers to research commercialisation.
The Science, Innovation and Technology Committee’s report emphasises that the UK is “flying blind” when it comes to public and private R&D spending, with major R&D funders unable to properly measure and map levels of investment, their outputs, and regional…
— Financing brings total funds committed to date to >$95 million
— Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory diseases
— Expands the leadership team with exceptional development executives to propel the clinical advancement of the pipeline
Cambridge, UK, March 17, 2026 – Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases, today announced the closing of a $…
Free-to-use software version available for academic and non-profit researchers worldwide
Intuitive system provides robust data management tools to support scientific collaboration and engagement with funding bodies through streamlined adherence to FAIR data principles
Silverstone, UK, 16 March 2026: Lab Thread Ltd, a UK-based life science software company, today announced the release of a free of charge version of the Company’s Unified Lab Software Platform, available to academic and non-profit researchers worldwide. The software provides a range of core modules tailored to support early-…
Penningtons Manches Cooper has partnered with Beauhurst, a leading private company data platform, to launch its latest report on the UK spinouts landscape, Investment into Spinouts 2026.
The publication offers a comprehensive overview of investment into UK spinouts, including trends in equity deployment, grant funding, regional performance and sector level dynamics.
It highlights the continued strength of the UK’s ‘Golden Triangle’ universities, with Cambridge, Oxford and London again securing the highest levels of spinout investment. It also examines the rise of early stage dealmaking, the…
Wes Streeting, Secretary of State for Health and Social Care Marks Official Launch of Health Innovation Hub
Glasgow’s newest purpose-built life sciences laboratory facility, the Health Innovation Hub (HiH), has been officially opened by Wes Streeting, Secretary of State for Health and Social Care following a launch event (5 March). This marks a major milestone for Scotland’s life sciences and the healthcare innovation ecosystem in Glasgow City Region.
Developed and operated by Kadans Science Partner, in collaboration with the University of Glasgow’s Living Laboratory for Precision Medicine,…
We’re pleased to share our latest learning opportunities, including newly added training courses and upcoming webinars designed to support professionals across the life sciences sector. Whether you’re looking to build new skills or deepen your expertise, explore the options below and find the right learning opportunity for you.
________________________________________________
One Nucleus Training
25-26 March 2026 | IOSH Approved Biological Safety - Management and Practice (2 day course) Register Here...
This two-day, IOSH-approved course develops your biosafety expertise,…
A podcast for the rising stars of the start-up community
Marks & Clerk presents a podcast series created specifically for the start-up community, helping founders understand the importance of embedding intellectual property (IP) into their business strategy from day one.
Featuring insights from experienced founders, investors and commercialisation experts, this series addresses the realities of IP strategy, funding, market validation and the challenges of scaling technology. Each episode offers clear, practical guidance - from navigating university licensing to overcoming the "three…
BOSTON, MA and LONDON, UK – March 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Syntis Bio, Inc. and is pleased to announce the placement of David Rosenbaum, Ph.D. as Chief Development Officer (CDO). Syntis Bio is a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine to treat obesity and rare metabolic diseases. As CDO, Dr. Rosenbaum will oversee the company’s clinical and technical development…